Effective use of PI3K inhibitor BKM120 and PARP inhibitor Olaparib to treat PIK3CA mutant ovarian cancer

Recent preclinical studies revealed the efficacy of combined use of PI3K inhibitor BKM120 and PARP inhibitor Olaparib in breast and prostate cancers. The current study investigated the effect of such drug combination on ovarian cancer. Here we showed that combined inhibition of PI3K and PARP effecti...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Oncotarget
Main Authors: Wang, Dong, Wang, Min, Jiang, Nan, Zhang, Yuan, Bian, Xing, Wang, Xiaoqing, Roberts, Thomas M., Zhao, Jean J., Liu, Pixu, Cheng, Hailing
Formato: Artigo
Idioma:Inglês
Publicado em: Impact Journals LLC 2016
Assuntos:
Research Paper
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4914348/
https://ncbi.nlm.nih.gov/pubmed/26909613
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.7549
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados